Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–35 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: r-metHuLeptin Clear all
Completed Phase 2 Interventional Results available

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

NCT00819234
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Pramlintide and Metreleptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arkansas • Santa Rosa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Leptin Treatment on Weight Loss

NCT00050791
View directory record Official record
Conditions
Obesity
Interventions
Leptin, Very Low Calorie Diet
Drug · Behavioral
Lead sponsor
Rockefeller University
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Role of Leptin in the Neuroendocrine and Immune Response to Fasting

NCT00140231
View directory record Official record
Conditions
Fasting
Interventions
r-metHuLeptin, placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Leptin in Human Energy and Neuroendocrine Homeostasis

NCT00265980
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Subcutaneous Placebo, Leptin
Drug
Lead sponsor
Columbia University
Other
Eligibility
19 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

NCT00691158
View directory record Official record
Conditions
Obesity
Interventions
Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

MEASuRE: Metreleptin Effectiveness And Safety Registry

NCT02325674
View directory record Official record
Conditions
Generalised Lipodystrophy, Partial Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Short-term Effects of Leptin in People With Lipodystrophy

NCT01778556
View directory record Official record
Conditions
Lipodystrophy
Interventions
Metreleptin
Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
14 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341
View directory record Official record
Conditions
Partial Lipodystrophy
Interventions
metreleptin, Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
12 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244
View directory record Official record
Conditions
HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions
r-metHuLeptin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Leptin Administration After Roux-en-Y Gastric Bypass

NCT00710814
View directory record Official record
Conditions
Overweight
Interventions
Leptin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Sep 28, 2026, 9:03 PM EDT